Bleomycin hydrochloride is a natural antibiotic, an inhibitor of DNA synthesis. It binds to nuclear DNA, targeting and killing dividing cells in G2 and M phases. It exhibits anticancer activity, showing efficacy against squamous cell carcinoma (SCC) with an IC50 of 4.0 nM in the UT-SCC-19A cell line.

Nigericin is an antibiotic derived from Streptomyces hygroscopicus that acts as a K+/H+ ionophore, which causes the efflux of potassium from the cell and, thus, influences the mitochondria membrane potential. It also induces pyroptosis in macrophages by activating NLRP3 inflammasome.

Nigericin is an antibiotic derived from Streptomyces hygroscopicus that acts as a K+/H+ ionophore, which causes the efflux of potassium from the cell and, thus, influences the mitochondria membrane potential. It also induces pyroptosis in macrophages by activating NLRP3 inflammasome.

Nigericin is an antibiotic derived from Streptomyces hygroscopicus that acts as a K+/H+ ionophore, which causes the efflux of potassium from the cell and, thus, influences the mitochondria membrane potential. It also induces pyroptosis in macrophages by activating NLRP3 inflammasome.

Nigericin is an antibiotic derived from Streptomyces hygroscopicus that acts as a K+/H+ ionophore, which causes the efflux of potassium from the cell and, thus, influences the mitochondria membrane potential. It also induces pyroptosis in macrophages by activating NLRP3 inflammasome.

Etomoxir ((R)-(+)-Etomoxir) is an irreversible, small-molecule inhibitor of carnitine palmitoyl-transferase 1a (CPT1a). It inhibits fatty acid oxidation (FAO) and may have potential in treating diabetes, inflammation, cancer and cardiac metabolic diseases.

Carboxy-PTIO potassium is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO potassium can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.

BAP1-IN-1 is a small-molecule inhibitor of BRCA1 associated protein 1 (BAP1) catalytic activity in vitro with an IC50 of 0.1-1 μM. It exhibits a potential therapeutic target for leukemia.

BAP1-IN-1 is a small-molecule inhibitor of BRCA1 associated protein 1 (BAP1) catalytic activity in vitro with an IC50 of 0.1-1 μM. It exhibits a potential therapeutic target for leukemia.

BAP1-IN-1 is a small-molecule inhibitor of BRCA1 associated protein 1 (BAP1) catalytic activity in vitro with an IC50 of 0.1-1 μM. It exhibits a potential therapeutic target for leukemia.